Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F09%3A00103086" target="_blank" >RIV/00843989:_____/09:00103086 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/S1474-4422(09)70237-6" target="_blank" >http://dx.doi.org/10.1016/S1474-4422(09)70237-6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S1474-4422(09)70237-6" target="_blank" >10.1016/S1474-4422(09)70237-6</a>
Alternative languages
Result language
angličtina
Original language name
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
Original language description
Background The Betaferon/Betaseron in newly emerging multiple sclerosis for initial treatment (BENEFIT) trial investigated the effect of treatment with interferon beta-1b after a clinically isolated syndrome. The 5-year active treatment extension compares the effects of early and delayed treatment with interferon beta-1b on time to clinically definite multiple sclerosis (CDMS) and other disease outcomes, including disability progression. Methods Patients with a first event suggestive of multiple sclerosis and a minimum of two clinically silent lesions in MRI were randomly assigned to receive interferon beta-1b 250 mu g (n=292; early treatment) or placebo (n=176; delayed treatment) subcutaneously every other day for 2 years, or until diagnosis of CDMS.All patients were then eligible to enter a prospectively planned follow-up phase with open-label interferon beta-1b up to a maximum of 5 years after randomisation. Patients and study personnel remained unaware of initial treatment allocat
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FH - Neurology, neuro-surgery, nuero-sciences
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2009
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Lancet Neurology
ISSN
1474-4422
e-ISSN
—
Volume of the periodical
8
Issue of the periodical within the volume
11
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
987-997
UT code for WoS article
000271309600011
EID of the result in the Scopus database
—